A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy

J. A. O'Shaughnessy, D. J. Venzon, M. Gossard, M. H. Noone, A. Denicoff, A. Tolcher, D. Danforth, J. Jacobson, P. Keegan, L. Miller, C. Chow, B. Goldspiel, K. H. Cowan

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Cumulative thrombocytopenia is a dose-limiting toxicity of dose-intensive chemotherapy for advanced breast cancer. In this phase I study, we have studied the hematologic toxicity associated with sequential interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF; molgramostim) administration after multiple cycles of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy compared with that after concurrent cytokine administration or to each cytokine administered alone. Ninety-three patients with advanced breast cancer were treated with five cycles of FLAC chemotherapy and either IL-3 alone, GM-CSF alone, sequential IL-3 and GM-CSF administered by schedule A (5 days of IL-3 followed by 10 days of GM-CSF) or schedule B (9 days of IL-3 followed by 6 days of GM-CSF), or concurrent administration of IL-3 and GM-CSF for 15 days. Cohorts of patients were treated with one of four dose levels of IL-3 (1, 2.5, 5, and 10 μg/kg) administered subcutaneously for each schedule of cytokine administration. The GM-CSF dose in all schedules was 5 μg/kg/day. Sequential IL-3 and GM-CSF (schedule B) was associated with higher platelet nadirs, shorter durations of platelet counts less than 50,000/μL, and the need for fewer platelet transfusions over five cycles of FLAC chemotherapy compared with concurrent cytokines, sequential IL-3 and GM-CSF schedule A, and GM-CSF alone. Concurrent IL-3 and GM-CSF was associated with unexpected platelet toxicity. The duration of granulocytopenia after FLAC chemotherapy was significantly worse with IL-3 alone compared with each of the GM-CSF- containing cytokine regimens. Although no cycle 1 maximum tolerated dose for IL-3 was defined in this study, 5 μg/kg was well tolerated over multiple cycles of therapy and is recommended for future studies. The data from this phase I study suggest that sequential IL-3 and GM-CSF with IL-3 administered for 9 days before beginning GM-CSF may be superior to shorter durations of IL-3 administered sequentially with GM-CSF, to concurrent IL-3 and GM-CSF, and to either colony-stimulating factor alone in ameliorating the cumulative hematologic toxicity associated with multiple cycles of FLAC chemotherapy. Additional studies of sequential IL-3 and GM-CSF are warranted.

Original languageEnglish (US)
Pages (from-to)2913-2921
Number of pages9
JournalBlood
Volume86
Issue number8
StatePublished - Nov 9 1995

Fingerprint

Chemotherapy
Leucovorin
Interleukin-3
Granulocyte-Macrophage Colony-Stimulating Factor
Fluorouracil
Doxorubicin
Cyclophosphamide
Breast Neoplasms
Drug Therapy
Appointments and Schedules
Platelets
Toxicity
Cytokines
Blood Platelets
Colony-Stimulating Factors
Platelet Transfusion
Agranulocytosis
Maximum Tolerated Dose

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy. / O'Shaughnessy, J. A.; Venzon, D. J.; Gossard, M.; Noone, M. H.; Denicoff, A.; Tolcher, A.; Danforth, D.; Jacobson, J.; Keegan, P.; Miller, L.; Chow, C.; Goldspiel, B.; Cowan, K. H.

In: Blood, Vol. 86, No. 8, 09.11.1995, p. 2913-2921.

Research output: Contribution to journalArticle

O'Shaughnessy, JA, Venzon, DJ, Gossard, M, Noone, MH, Denicoff, A, Tolcher, A, Danforth, D, Jacobson, J, Keegan, P, Miller, L, Chow, C, Goldspiel, B & Cowan, KH 1995, 'A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy', Blood, vol. 86, no. 8, pp. 2913-2921.
O'Shaughnessy, J. A. ; Venzon, D. J. ; Gossard, M. ; Noone, M. H. ; Denicoff, A. ; Tolcher, A. ; Danforth, D. ; Jacobson, J. ; Keegan, P. ; Miller, L. ; Chow, C. ; Goldspiel, B. ; Cowan, K. H. / A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy. In: Blood. 1995 ; Vol. 86, No. 8. pp. 2913-2921.
@article{5c3fcce8994e4315a4f06b3518e647cc,
title = "A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy",
abstract = "Cumulative thrombocytopenia is a dose-limiting toxicity of dose-intensive chemotherapy for advanced breast cancer. In this phase I study, we have studied the hematologic toxicity associated with sequential interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF; molgramostim) administration after multiple cycles of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy compared with that after concurrent cytokine administration or to each cytokine administered alone. Ninety-three patients with advanced breast cancer were treated with five cycles of FLAC chemotherapy and either IL-3 alone, GM-CSF alone, sequential IL-3 and GM-CSF administered by schedule A (5 days of IL-3 followed by 10 days of GM-CSF) or schedule B (9 days of IL-3 followed by 6 days of GM-CSF), or concurrent administration of IL-3 and GM-CSF for 15 days. Cohorts of patients were treated with one of four dose levels of IL-3 (1, 2.5, 5, and 10 μg/kg) administered subcutaneously for each schedule of cytokine administration. The GM-CSF dose in all schedules was 5 μg/kg/day. Sequential IL-3 and GM-CSF (schedule B) was associated with higher platelet nadirs, shorter durations of platelet counts less than 50,000/μL, and the need for fewer platelet transfusions over five cycles of FLAC chemotherapy compared with concurrent cytokines, sequential IL-3 and GM-CSF schedule A, and GM-CSF alone. Concurrent IL-3 and GM-CSF was associated with unexpected platelet toxicity. The duration of granulocytopenia after FLAC chemotherapy was significantly worse with IL-3 alone compared with each of the GM-CSF- containing cytokine regimens. Although no cycle 1 maximum tolerated dose for IL-3 was defined in this study, 5 μg/kg was well tolerated over multiple cycles of therapy and is recommended for future studies. The data from this phase I study suggest that sequential IL-3 and GM-CSF with IL-3 administered for 9 days before beginning GM-CSF may be superior to shorter durations of IL-3 administered sequentially with GM-CSF, to concurrent IL-3 and GM-CSF, and to either colony-stimulating factor alone in ameliorating the cumulative hematologic toxicity associated with multiple cycles of FLAC chemotherapy. Additional studies of sequential IL-3 and GM-CSF are warranted.",
author = "O'Shaughnessy, {J. A.} and Venzon, {D. J.} and M. Gossard and Noone, {M. H.} and A. Denicoff and A. Tolcher and D. Danforth and J. Jacobson and P. Keegan and L. Miller and C. Chow and B. Goldspiel and Cowan, {K. H.}",
year = "1995",
month = "11",
day = "9",
language = "English (US)",
volume = "86",
pages = "2913--2921",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy

AU - O'Shaughnessy, J. A.

AU - Venzon, D. J.

AU - Gossard, M.

AU - Noone, M. H.

AU - Denicoff, A.

AU - Tolcher, A.

AU - Danforth, D.

AU - Jacobson, J.

AU - Keegan, P.

AU - Miller, L.

AU - Chow, C.

AU - Goldspiel, B.

AU - Cowan, K. H.

PY - 1995/11/9

Y1 - 1995/11/9

N2 - Cumulative thrombocytopenia is a dose-limiting toxicity of dose-intensive chemotherapy for advanced breast cancer. In this phase I study, we have studied the hematologic toxicity associated with sequential interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF; molgramostim) administration after multiple cycles of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy compared with that after concurrent cytokine administration or to each cytokine administered alone. Ninety-three patients with advanced breast cancer were treated with five cycles of FLAC chemotherapy and either IL-3 alone, GM-CSF alone, sequential IL-3 and GM-CSF administered by schedule A (5 days of IL-3 followed by 10 days of GM-CSF) or schedule B (9 days of IL-3 followed by 6 days of GM-CSF), or concurrent administration of IL-3 and GM-CSF for 15 days. Cohorts of patients were treated with one of four dose levels of IL-3 (1, 2.5, 5, and 10 μg/kg) administered subcutaneously for each schedule of cytokine administration. The GM-CSF dose in all schedules was 5 μg/kg/day. Sequential IL-3 and GM-CSF (schedule B) was associated with higher platelet nadirs, shorter durations of platelet counts less than 50,000/μL, and the need for fewer platelet transfusions over five cycles of FLAC chemotherapy compared with concurrent cytokines, sequential IL-3 and GM-CSF schedule A, and GM-CSF alone. Concurrent IL-3 and GM-CSF was associated with unexpected platelet toxicity. The duration of granulocytopenia after FLAC chemotherapy was significantly worse with IL-3 alone compared with each of the GM-CSF- containing cytokine regimens. Although no cycle 1 maximum tolerated dose for IL-3 was defined in this study, 5 μg/kg was well tolerated over multiple cycles of therapy and is recommended for future studies. The data from this phase I study suggest that sequential IL-3 and GM-CSF with IL-3 administered for 9 days before beginning GM-CSF may be superior to shorter durations of IL-3 administered sequentially with GM-CSF, to concurrent IL-3 and GM-CSF, and to either colony-stimulating factor alone in ameliorating the cumulative hematologic toxicity associated with multiple cycles of FLAC chemotherapy. Additional studies of sequential IL-3 and GM-CSF are warranted.

AB - Cumulative thrombocytopenia is a dose-limiting toxicity of dose-intensive chemotherapy for advanced breast cancer. In this phase I study, we have studied the hematologic toxicity associated with sequential interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF; molgramostim) administration after multiple cycles of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy compared with that after concurrent cytokine administration or to each cytokine administered alone. Ninety-three patients with advanced breast cancer were treated with five cycles of FLAC chemotherapy and either IL-3 alone, GM-CSF alone, sequential IL-3 and GM-CSF administered by schedule A (5 days of IL-3 followed by 10 days of GM-CSF) or schedule B (9 days of IL-3 followed by 6 days of GM-CSF), or concurrent administration of IL-3 and GM-CSF for 15 days. Cohorts of patients were treated with one of four dose levels of IL-3 (1, 2.5, 5, and 10 μg/kg) administered subcutaneously for each schedule of cytokine administration. The GM-CSF dose in all schedules was 5 μg/kg/day. Sequential IL-3 and GM-CSF (schedule B) was associated with higher platelet nadirs, shorter durations of platelet counts less than 50,000/μL, and the need for fewer platelet transfusions over five cycles of FLAC chemotherapy compared with concurrent cytokines, sequential IL-3 and GM-CSF schedule A, and GM-CSF alone. Concurrent IL-3 and GM-CSF was associated with unexpected platelet toxicity. The duration of granulocytopenia after FLAC chemotherapy was significantly worse with IL-3 alone compared with each of the GM-CSF- containing cytokine regimens. Although no cycle 1 maximum tolerated dose for IL-3 was defined in this study, 5 μg/kg was well tolerated over multiple cycles of therapy and is recommended for future studies. The data from this phase I study suggest that sequential IL-3 and GM-CSF with IL-3 administered for 9 days before beginning GM-CSF may be superior to shorter durations of IL-3 administered sequentially with GM-CSF, to concurrent IL-3 and GM-CSF, and to either colony-stimulating factor alone in ameliorating the cumulative hematologic toxicity associated with multiple cycles of FLAC chemotherapy. Additional studies of sequential IL-3 and GM-CSF are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0028863464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028863464&partnerID=8YFLogxK

M3 - Article

C2 - 7579383

AN - SCOPUS:0028863464

VL - 86

SP - 2913

EP - 2921

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -